Market capitalization | $4.20b |
Enterprise Value | $4.40b |
P/E (TTM) P/E ratio | 101.84 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 9.02 |
P/S ratio (TTM) P/S ratio | 8.61 |
P/B ratio (TTM) P/B ratio | 15.78 |
Revenue growth (TTM) Revenue growth | 64.43% |
Revenue (TTM) Revenue | $488.23m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
10 Analysts have issued a TransMedics Group, Inc. forecast:
10 Analysts have issued a TransMedics Group, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 488 488 |
64%
64%
|
|
Gross Profit | 290 290 |
57%
57%
|
|
EBITDA | 53 53 |
474%
474%
|
EBIT (Operating Income) EBIT | 53 53 |
469%
469%
|
Net Profit | 49 49 |
580%
580%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
Head office | United States |
CEO | Waleed Hassanein |
Employees | 728 |
Founded | 1998 |
Website | www.transmedics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.